Company intelligence / Profile preview
Radionetics Oncology
San Diego, California, United Statesradionetics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Radionetics Oncology has initiated a Phase I study for its lead candidate, a gallium-based radioligand conjugate targeting MC2R in adrenocortical carcinoma. The company plans additional clinical programs in breast and lung cancers. Its approach leverages novel GPCR targets with small molecule precision for selective tumor targeting using radioactive payloads.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule radioligandsRadiopharmaceuticalsNonpeptide-targeted radiotherapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Eli Lilly & Company – $140M upfront payment for access to pipeline/platform plus exclusive future acquisition right ($1B option)Crinetics Pharmaceuticals – technology licensing/research collaboration agreement at formation
Beyond the preview
Go deeper on Radionetics Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Radionetics Oncology.